Doximity, Inc. (NASDAQ:DOCS) Shares Sold by Raymond James & Associates

Raymond James & Associates trimmed its position in Doximity, Inc. (NASDAQ:DOCS – Get Rating) by 7.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 175,910 shares of the company’s stock after selling 14,651 shares during the period. Raymond James & Associates’ holdings in Doximity were worth $5,904,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Doximity by 70.8% during the third quarter. BlackRock Inc. now owns 8,905,675 shares of the company’s stock valued at $269,130,000 after buying an additional 3,693,016 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Doximity by 13.1% during the third quarter. Vanguard Group Inc. now owns 8,652,470 shares of the company’s stock worth $261,478,000 after buying an additional 1,000,328 shares in the last quarter. Eventide Asset Management LLC grew its position in Doximity by 125.5% in the third quarter. Eventide Asset Management LLC now owns 3,411,287 shares of the company’s stock worth $103,089,000 after buying an additional 1,898,685 shares during the last quarter. Clearbridge Investments LLC lifted its position in shares of Doximity by 559.5% during the 1st quarter. Clearbridge Investments LLC now owns 2,682,876 shares of the company’s stock valued at $139,751,000 after acquiring an additional 2,276,056 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Doximity by 141.3% during the 1st quarter. Invesco Ltd. now owns 2,410,842 shares of the company’s stock worth $125,581,000 after acquiring an additional 1,411,849 shares in the last quarter. 52.48% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Timothy S. Cabral sold 7,500 shares of the stock in a transaction dated Tuesday, April 11th. The stock was sold at an average price of $35.00, for a total transaction of $262,500.00. Following the transaction, the director now owns 4,714 shares of the company’s stock, valued at approximately $164,990. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 45.21% of the company’s stock.

Doximity Trading Down 3.8 %

Shares of NASDAQ:DOCS opened at $32.04 on Monday. The stock has a market capitalization of $6.20 billion, a PE ratio of 61.62, a P/E/G ratio of 6.65 and a beta of 0.87. Doximity, Inc. has a 1 year low of $22.91 and a 1 year high of $47.46. The firm has a fifty day moving average price of $33.36 and a 200 day moving average price of $33.22.

Wall Street Analyst Weigh In

DOCS has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $45.00 target price on shares of Doximity in a report on Friday, February 10th. Wells Fargo & Company downgraded shares of Doximity from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $39.00 to $37.00 in a research note on Monday, May 1st. Canaccord Genuity Group dropped their price target on Doximity from $42.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, February 10th. JPMorgan Chase & Co. decreased their price objective on Doximity from $60.00 to $30.00 and set an “underweight” rating for the company in a research report on Friday, February 17th. Finally, Piper Sandler upped their target price on Doximity from $35.00 to $38.00 in a report on Friday, February 10th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.00.

Doximity Company Profile

(Get Rating)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.